Banner for leaf pages 2

Asenapine (Saphris)

Also known as Saphris

Asenapine (INN, trade names Saphris, Sycrest) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 merger with Organon International. Development of the drug, through Phase III trials, began while Organon was still a part of Akzo Nobel. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in clinical trials of asenapine, and the FDA accepted the manufacturer's NDA on November 26, 2007 for standard review.

Source: Wikipedia

Estimated Total Cost: $439.04 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed asenapine to treat bipolar disorder, rabies, blastomycosis, and west nile virus.

What drug interactions are known?

Do not take asenapine if you are taking any of the following:

Critical Interactions

Significant Interactions

What side effects are related?

Patients taking asenapine most commonly experience side effects like headache, insomnia, and constipation.

Ajax-loader Loading...